BIOMOTION SCIENCES ORDINARY SHARES

NASDAQ: SLXN (Silexion Therapeutics Corp)

Kemas kini terakhir: 04 May, 2:03AM

1.00

0.00 (0.00%)

  • 1H 0.00%
  • 5H 0.60%
  • 1B -2.91%
  • 6B 224.68%
  • Tahun Ke Tarikh -49.75%
  • 1T -91.11%
  • 5T -90.00%
Penutupan Terdahulu 1.00
Buka 0.990
Jumlah Dagangan 160,837
Purata Dagangan (3B) 4,927,637
Modal Pasaran 8,692,390
Julat 52 Minggu
0.207 (-79%) — 13.56 (1255%)
Tarikh Pendapatan 12 Nov 2024 - 18 Nov 2024
EPS Cair (TTM) -26.36
Pertumbuhan Pendapatan Suku Tahunan (YOY) 1,405.80%
Jumlah Hutang/Ekuiti (D/E MRQ) 8.94%
Nisbah Semasa (MRQ) 0.640
Aliran Tunai Operasi (OCF TTM) -8.40 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -2.41 M
Pulangan Atas Aset (ROA TTM) -193.54%
Pulangan Atas Ekuiti (ROE TTM) -116.66%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Menurun Menurun
Biotechnology (Global) Menurun Menurun
Stok Silexion Therapeutics Corp Menaik -

AISkor Stockmoo

0.6
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam NA
Volatiliti Harga -2.0
Purata Bergerak Teknikal 2.5
Osilator Teknikal 0.5
Purata 0.63

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
SLXN 9 M - - -
ASND 9 B - - -
PROK 2 B - - 97.15
ELVN 874 M - - 2.61
GYRE 786 M - 446.00 13.50
AVBP 706 M - - 2.36

Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.
Sektor Healthcare
Industri Biotechnology
% Dimiliki oleh Orang Dalam 5.98%
% Dimiliki oleh Institusi 10.54%

Pemilikan

Nama Tarikh Syer Dipegang
Meyer Handelman Co 31 Mar 2025 32,967
5.405.404.204.203.003.001.801.800.6000.600Harga Sasaran MedianQ4 '24Q4 '24Q1 '25Q1 '25
Julat 52 Minggu
0.207 (-79%) — 13.56 (1255%)
Median 5.00 (400.00%)
Jumlah 1 Beli
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Maxim Group 20 Mar 2025 5.00 (400.00%) Beli 1.11

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
21 May 2025 Pengumuman Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204’s Potential Impact on Colorectal and Lung Cancer
13 May 2025 Pengumuman Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
23 Apr 2025 Pengumuman Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities
28 Mar 2025 Pengumuman Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data
21 Mar 2025 Pengumuman Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference
18 Mar 2025 Pengumuman Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
17 Mar 2025 Pengumuman PESG Report: Silexion Therapeutics’ Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment
05 Mar 2025 Pengumuman Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models
03 Mar 2025 Pengumuman PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational
25 Feb 2025 Pengumuman Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204
1.031.030.9870.9870.9430.9430.8990.8990.8550.855May 6May 6May 7May 7May 8May 8May 9May 9May 12May 12May 13May 13May 14May 14May 15May 15

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.0000.000-0.020-0.020-0.040-0.040-0.060-0.060-0.080-0.080MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda